Literature DB >> 10193766

Prostanoid receptors involved in the relaxation of human bronchial preparations.

X Norel1, L Walch, C Labat, J P Gascard, E Dulmet, C Brink.   

Abstract

1. Iloprost and cicaprost (IP-receptor agonists) induced relaxations in the histamine- (50 microM) contracted human bronchial preparations (pD2 values, 6.63+/-0.12 and 6.86+/-0.08; Emax values, 90+/-04 and 65+/-08% of the papaverine response for iloprost (n=6) and cicaprost (n=3), respectively). 2. Prostaglandin E2 (PGE2) and misoprostol (EP-receptor agonist) relaxed the histamine-contracted human bronchial preparations (pD2 values, 7.13+/-0.07 and 6.33+/-0.28; Emax values, 67+/-04 and 57+/-08% of the papaverine response for PGE2 (n=14) and misoprostol (n=4), respectively). In addition, both relaxations were inhibited by AH6809 (DP/EP1/EP2-receptor antagonist; 3 microM; n=5-6). 3. The PGE2-induced relaxations of human bronchial preparations were not modified by treatment with AH23848B (TP/EP4-receptor antagonist; 30 microM; n=4). 4. The contracted human bronchial preparations were significantly relaxed by prostaglandin D2 (PGD2) or by BW245C a DP-receptor agonist. However, these responses did not exceed 40% of the relaxation induced by papaverine. In addition, the relaxations induced by PGD2 were significantly inhibited by treatment with a DP-receptor antagonist BWA868C (0.1 microM; n=3). 5. These data suggest that the relaxation of human isolated bronchial preparations induced by prostanoids involved IP-, EP2- and to a lesser extent DP-receptors but not EP4-receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193766      PMCID: PMC1571227          DOI: 10.1038/sj.bjp.0702392

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Relaxation of isolated human pulmonary muscle preparations with prostacyclin (PGI2) and its analogs.

Authors:  I Haye-Legrand; B Bourdillat; C Labat; J Cerrina; X Norel; J Benveniste; C Brink
Journal:  Prostaglandins       Date:  1987-06

2.  AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

Authors:  R J Keery; P Lumley
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

3.  Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.

Authors:  R A Armstrong; R A Lawrence; R L Jones; N H Wilson; A Collier
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

4.  Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979.

Authors:  P J Gardiner
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

5.  Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.

Authors:  J E Merritt; T J Hallam; A M Brown; I Boyfield; D G Cooper; D M Hickey; A A Jaxa-Chamiec; A J Kaumann; M Keen; E Kelly
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

6.  Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

7.  (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets.

Authors:  A Corsini; G C Folco; R Fumagalli; S Nicosia; M A Noe; D Oliva
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

8.  The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

9.  The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.

Authors:  H Giles; P Leff; M L Bolofo; M G Kelly; A D Robertson
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

10.  Different responsiveness of prostaglandin D2-sensitive systems to prostaglandin D2 and its analogues.

Authors:  S Narumiya; N Toda
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

View more
  25 in total

1.  Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation.

Authors:  Linda J Kay; Wilfred W Yeo; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

2.  Endogenous Gs-coupled receptors in smooth muscle exhibit differential susceptibility to GRK2/3-mediated desensitization.

Authors:  Kok Choi Kong; Uma Gandhi; T J Martin; Candace B Anz; Huandong Yan; Anna M Misior; Rodolfo M Pascual; Deepak A Deshpande; Raymond B Penn
Journal:  Biochemistry       Date:  2008-08-09       Impact factor: 3.162

3.  Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles.

Authors:  L J Janssen; M Premji; S Netherton; J Coruzzi; H Lu-Chao; P G Cox
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Role of PGE(2) in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea.

Authors:  R S Lan; D A Knight; G A Stewart; P J Henry
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension.

Authors:  Gulsev Ozen; Chabha Benyahia; Salma Mani; Kamel Boukais; Adam M Silverstein; Richard Bayles; Andrew C Nelsen; Yves Castier; Claire Danel; Hervé Mal; Lucie H Clapp; Dan Longrois; Xavier Norel
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

6.  Prostanoid receptors involved in the relaxation of human pulmonary vessels.

Authors:  L Walch; C Labat; J P Gascard; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Prostanoids and the cough reflex.

Authors:  Sarah A Maher; Maria G Belvisi
Journal:  Lung       Date:  2009-10-15       Impact factor: 2.584

8.  Rabbit plasma metabolomic analysis of Nitroproston®: a multi target natural prostaglandin based-drug.

Authors:  Ksenia Shestakova; Alex Brito; Natalia V Mesonzhnik; Natalia E Moskaleva; Ksenia O Kurynina; Natalia M Grestskaya; Igor V Serkov; Igor I Lyubimov; Vladimir V Bezuglov; Svetlana A Appolonova
Journal:  Metabolomics       Date:  2018-08-20       Impact factor: 4.290

Review 9.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

Review 10.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.